{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=IBD&page=12",
    "query": {
      "condition": "IBD",
      "page": 12
    },
    "page_size": 10
  },
  "pagination": {
    "page": 12,
    "page_size": 10,
    "total_count": 1553,
    "total_pages": 156,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=IBD&page=13&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=IBD&page=11&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-22T01:01:51.629Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00333788",
      "title": "Follow-up to Welcome Study C87042 [NCT00308581] Examining Certolizumab Pegol (CDP870) in Subjects With Crohn's Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Crohn's Disease"
      ],
      "interventions": [
        {
          "name": "Certolizumab pegol (CDP870)",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "UCB Pharma",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 233,
      "start_date": "2006-10",
      "completion_date": "2010-04",
      "has_results": true,
      "last_update_posted_date": "2018-08-07",
      "last_synced_at": "2026-10-22T01:01:51.629Z",
      "location_count": 19,
      "location_summary": "Gainesville, Florida • Atlanta, Georgia • Chicago, Illinois + 16 more",
      "locations": [
        {
          "city": "Gainesville",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "Louisville",
          "state": "Kentucky"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00333788"
    },
    {
      "nct_id": "NCT01150890",
      "title": "Brodalumab (AMG 827) in Adults With Moderate to Severe Crohn's Disease",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Crohn's Disease"
      ],
      "interventions": [
        {
          "name": "Brodalumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Amgen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 130,
      "start_date": "2010-11-09",
      "completion_date": "2011-10-15",
      "has_results": true,
      "last_update_posted_date": "2022-01-03",
      "last_synced_at": "2026-10-22T01:01:51.629Z",
      "location_count": 18,
      "location_summary": "Birmingham, Alabama • Dothan, Alabama • Lowell, Arkansas + 15 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Dothan",
          "state": "Alabama"
        },
        {
          "city": "Lowell",
          "state": "Arkansas"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01150890"
    },
    {
      "nct_id": "NCT02162862",
      "title": "Treating Disrupted Sleep in Individuals With Inflammatory Bowel Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Sleep Disturbance",
        "Fatigue",
        "Inflammatory Bowel Disease"
      ],
      "interventions": [
        {
          "name": "Behavioral Counseling",
          "type": "BEHAVIORAL"
        },
        {
          "name": "bupropion-SR",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL",
        "DRUG"
      ],
      "sponsor": "Eva Szigethy",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "15 Years",
        "maximum_age": "30 Years",
        "sex": "ALL",
        "summary": "15 Years to 30 Years"
      },
      "enrollment_count": 99,
      "start_date": "2013-07",
      "completion_date": "2016-06-30",
      "has_results": true,
      "last_update_posted_date": "2017-09-13",
      "last_synced_at": "2026-10-22T01:01:51.629Z",
      "location_count": 2,
      "location_summary": "Pittsburgh, Pennsylvania",
      "locations": [
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        },
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02162862"
    },
    {
      "nct_id": "NCT01696942",
      "title": "Cimzia Versus Mesalamine for Crohn's Recurrence",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Crohn's Disease"
      ],
      "interventions": [
        {
          "name": "Cimzia",
          "type": "DRUG"
        },
        {
          "name": "Mesalamine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Milton S. Hershey Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 10,
      "start_date": "2013-02",
      "completion_date": "2016-06",
      "has_results": true,
      "last_update_posted_date": "2018-01-12",
      "last_synced_at": "2026-10-22T01:01:51.629Z",
      "location_count": 1,
      "location_summary": "Hershey, Pennsylvania",
      "locations": [
        {
          "city": "Hershey",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01696942"
    },
    {
      "nct_id": "NCT00113503",
      "title": "Imuran Dosing in Crohn's Disease Study",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Crohn's Disease"
      ],
      "interventions": [
        {
          "name": "Azathioprine weight-based dose",
          "type": "DRUG"
        },
        {
          "name": "Azathioprine individualised dose",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "10 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "10 Years to 70 Years"
      },
      "enrollment_count": 50,
      "start_date": "2005-07",
      "completion_date": "2007-12",
      "has_results": false,
      "last_update_posted_date": "2017-10-06",
      "last_synced_at": "2026-10-22T01:01:51.629Z",
      "location_count": 12,
      "location_summary": "Los Angeles, California • Atlanta, Georgia • Chicago, Illinois + 8 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00113503"
    },
    {
      "nct_id": "NCT01831427",
      "title": "Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of GS-5745 (Andecaliximab) in Adults With Moderate to Severe Active Ulcerative Colitis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Ulcerative Colitis"
      ],
      "interventions": [
        {
          "name": "Andecaliximab",
          "type": "DRUG"
        },
        {
          "name": "Placebo to match Andecaliximab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Gilead Sciences",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 74,
      "start_date": "2013-03-28",
      "completion_date": "2015-02-06",
      "has_results": true,
      "last_update_posted_date": "2021-02-01",
      "last_synced_at": "2026-10-22T01:01:51.629Z",
      "location_count": 6,
      "location_summary": "Monroe, Louisiana • Bethesda, Maryland • Chesterfield Township, MI 48047, Michigan + 3 more",
      "locations": [
        {
          "city": "Monroe",
          "state": "Louisiana"
        },
        {
          "city": "Bethesda",
          "state": "Maryland"
        },
        {
          "city": "Chesterfield Township, MI 48047",
          "state": "Michigan"
        },
        {
          "city": "Belton",
          "state": "Missouri"
        },
        {
          "city": "Durham",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01831427"
    },
    {
      "nct_id": "NCT00829595",
      "title": "Pneumococcal Vaccination in Patients With Inflammatory Bowel Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Inflammatory Bowel Disease",
        "Crohn Disease",
        "Ulcerative Colitis"
      ],
      "interventions": [
        {
          "name": "23-valent polysaccharide pneumococcal vaccine (Pneumovax TM)",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Cedars-Sinai Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 69,
      "start_date": "2005-05",
      "completion_date": "2007-12",
      "has_results": false,
      "last_update_posted_date": "2009-01-27",
      "last_synced_at": "2026-10-22T01:01:51.629Z",
      "location_count": 1,
      "location_summary": "Los Angeles, California",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00829595"
    },
    {
      "nct_id": "NCT01647412",
      "title": "Growth Hormone and Exclusion Diet Therapy in Juvenile Crohn's Disease",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Crohn's Disease"
      ],
      "interventions": [
        {
          "name": "Growth Hormone",
          "type": "DRUG"
        },
        {
          "name": "Nutraceutical Combination",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "Exclusion Diet",
          "type": "OTHER"
        },
        {
          "name": "Placebo Growth Hormone",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "DIETARY_SUPPLEMENT",
        "OTHER"
      ],
      "sponsor": "Columbia University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "10 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "10 Years to 17 Years"
      },
      "enrollment_count": 0,
      "start_date": "2012-03",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2015-04-13",
      "last_synced_at": "2026-10-22T01:01:51.629Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01647412"
    },
    {
      "nct_id": "NCT01233960",
      "title": "Evaluation of PROCHYMAL® for Treatment-refractory Moderate-to-severe Crohn's Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Crohn's Disease"
      ],
      "interventions": [
        {
          "name": "Prochymal®",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Mesoblast, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 73,
      "start_date": "2010-11-29",
      "completion_date": "2014-09-15",
      "has_results": false,
      "last_update_posted_date": "2026-03-11",
      "last_synced_at": "2026-10-22T01:01:51.629Z",
      "location_count": 16,
      "location_summary": "San Francisco, California • Clearwater, Florida • Winter Park, Florida + 11 more",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Clearwater",
          "state": "Florida"
        },
        {
          "city": "Winter Park",
          "state": "Florida"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Topeka",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01233960"
    },
    {
      "nct_id": "NCT06651281",
      "title": "Extension Study of Long-term Safety and Efficacy of Tulisokibart in Participants With Crohn's Disease or Ulcerative Colitis (MK-7240-011)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Crohn Disease",
        "Colitis, Ulcerative"
      ],
      "interventions": [
        {
          "name": "Tulisokibart",
          "type": "DRUG"
        },
        {
          "name": "Placebo to tulisokibart",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Merck Sharp & Dohme LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 1380,
      "start_date": "2024-11-25",
      "completion_date": "2037-12-17",
      "has_results": false,
      "last_update_posted_date": "2026-10-02",
      "last_synced_at": "2026-10-22T01:01:51.629Z",
      "location_count": 12,
      "location_summary": "Bristol, Connecticut • Ypsilanti, Michigan • Liberty, Missouri + 8 more",
      "locations": [
        {
          "city": "Bristol",
          "state": "Connecticut"
        },
        {
          "city": "Ypsilanti",
          "state": "Michigan"
        },
        {
          "city": "Liberty",
          "state": "Missouri"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Garland",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06651281"
    }
  ]
}